PL2315780T3 - Kompozycje i sposoby zastosowania przeciwciał terapeutycznych - Google Patents

Kompozycje i sposoby zastosowania przeciwciał terapeutycznych

Info

Publication number: PL2315780T3
Authority: PL; Poland
Prior art keywords: compositions; methods; therapeutic antibodies; antibodies; therapeutic
Prior art date: 2008-07-17

Application number

PL09797499T

Other languages

English (en)

Inventor

Christoph Heusser

Julia Neugebauer

Eveline Schaadt

Stefanie Urlinger

Maximilian Woisetschlaeger

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-07-17

Filing date

2009-07-15

Publication date

2016-01-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41073830&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2315780(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-07-15 Application filed by Novartis Ag filed Critical Novartis Ag

2016-01-29 Publication of PL2315780T3 publication Critical patent/PL2315780T3/pl

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Hematology (AREA)
Transplantation (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Oncology (AREA)
Biomedical Technology (AREA)
Pain & Pain Management (AREA)
Orthopedic Medicine & Surgery (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

PL09797499T 2008-07-17 2009-07-15 Kompozycje i sposoby zastosowania przeciwciał terapeutycznych PL2315780T3 (pl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
EP08160671		2008-07-17
EP09160326		2009-05-15
PCT/EP2009/059030 WO2010007082A1 (en)	2008-07-17	2009-07-15	Compositions and methods of use for therapeutic antibodies
EP09797499.2A EP2315780B8 (en)	2008-07-17	2009-07-15	Compositions and methods of use for therapeutic antibodies

Publications (1)

Publication Number	Publication Date
PL2315780T3 true PL2315780T3 (pl)	2016-01-29

Family

ID=41073830

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL09797499T PL2315780T3 (pl)	2008-07-17	2009-07-15	Kompozycje i sposoby zastosowania przeciwciał terapeutycznych

Country Status (40)

Country	Link
US (3)	US8106163B2 (pl)
EP (1)	EP2315780B8 (pl)
JP (2)	JP5767109B2 (pl)
KR (2)	KR101314369B1 (pl)
CN (1)	CN102119174B (pl)
AR (1)	AR072749A1 (pl)
AU (1)	AU2009272771B2 (pl)
BR (1)	BRPI0915928B8 (pl)
CA (1)	CA2730063C (pl)
CL (1)	CL2011000086A1 (pl)
CR (1)	CR11863A (pl)
CU (1)	CU23878B1 (pl)
CY (1)	CY1116800T1 (pl)
DK (1)	DK2315780T3 (pl)
DO (1)	DOP2011000016A (pl)
EA (1)	EA024492B1 (pl)
EC (1)	ECSP11010761A (pl)
ES (1)	ES2547270T3 (pl)
GE (1)	GEP20146129B (pl)
HR (1)	HRP20151227T1 (pl)
HU (1)	HUE025778T2 (pl)
IL (1)	IL210485A (pl)
JO (1)	JO3149B1 (pl)
MA (1)	MA32481B1 (pl)
MX (1)	MX2011000616A (pl)
MY (1)	MY158980A (pl)
NI (1)	NI201100017A (pl)
NZ (1)	NZ590057A (pl)
PE (1)	PE20110563A1 (pl)
PL (1)	PL2315780T3 (pl)
PT (1)	PT2315780E (pl)
RS (1)	RS54299B1 (pl)
SG (1)	SG193805A1 (pl)
SI (1)	SI2315780T1 (pl)
SM (1)	SMP201100010B (pl)
SV (1)	SV2011003807A (pl)
TW (1)	TWI508742B (pl)
UY (1)	UY31987A (pl)
WO (1)	WO2010007082A1 (pl)
ZA (1)	ZA201008952B (pl)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8470966B2 (en)	2007-08-10	2013-06-25	Protelica, Inc.	Universal fibronectin type III binding-domain libraries
US8680019B2 (en) *	2007-08-10	2014-03-25	Protelica, Inc.	Universal fibronectin Type III binding-domain libraries
EP2222846B1 (en) *	2007-08-10	2017-05-03	Protelix, Inc.	Universal fibronectin type iii binding-domain libraries
EP2648750B1 (en)	2010-12-10	2017-01-25	Novartis AG	Antibody formulation
JP2012153788A (ja) *	2011-01-25	2012-08-16	Nitto Denko Corp	光学用粘着シート
RU2676731C2 (ru) *	2011-05-13	2019-01-10	Ганимед Фармасьютикалз Аг	Антитела для лечения раковых заболеваний, при которых экспрессируется клаудин 6
US9216219B2 (en)	2012-06-12	2015-12-22	Novartis Ag	Anti-BAFFR antibody formulation
WO2015100246A1 (en)	2013-12-24	2015-07-02	Ossianix, Inc.	Baff selective binding compounds and related methods
CA2934965A1 (en)	2014-01-31	2016-03-17	Boehringer Ingelheim International Gmbh	Novel anti-baff antibodies
MA41044A (fr)	2014-10-08	2017-08-15	Novartis Ag	Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
EP3206711B1 (en)	2014-10-14	2023-05-31	Novartis AG	Antibody molecules to pd-l1 and uses thereof
MA41459A (fr)	2015-02-03	2017-12-12	Als Therapy Development Inst	Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l
EP3317301B1 (en)	2015-07-29	2021-04-07	Novartis AG	Combination therapies comprising antibody molecules to lag-3
WO2017019896A1 (en)	2015-07-29	2017-02-02	Novartis Ag	Combination therapies comprising antibody molecules to pd-1
WO2017019897A1 (en)	2015-07-29	2017-02-02	Novartis Ag	Combination therapies comprising antibody molecules to tim-3
EP4424322A3 (en)	2015-12-17	2025-04-16	Novartis AG	Antibody molecules to pd-1 and uses thereof
EP3413894B1 (en)	2016-02-10	2020-03-11	Novartis AG	Use of inhibitors of the activity or function of pi3k for the treatment of primary sjögren's syndrome
CN116041514A (zh) *	2016-06-06	2023-05-02	希望之城	Baff-r抗体及其用途
KR20250016462A (ko)	2016-12-21	2025-02-03	테네오바이오, 인코포레이티드	항-bcma 중쇄-단독 항체
US11197928B2 (en)	2017-01-13	2021-12-14	Board Of Regents, The University Of Texas System	Sustained production of high affinity antigen specific antibody by high dose BAFF receptor-targeting mAb-siRNA conjugate
CN110662768B (zh) *	2017-05-24	2024-01-30	Als治疗发展学会	治疗性抗cd40配体抗体
US11970540B2 (en) *	2017-06-20	2024-04-30	Teneobio, Inc.	Anti-BCMA heavy chain-only antibodies
EP4714502A2 (en) *	2018-07-20	2026-03-25	TeneoTwo, Inc.	Heavy chain antibodies binding to cd19
JPWO2020202839A1 (pl) *	2019-03-29	2020-10-08
TWI905099B (zh)	2019-05-21	2025-11-21	瑞士商諾華公司	Cd19 結合分子及其用途
CA3160207A1 (en) *	2019-11-06	2021-05-14	Novartis Ag	Treatment for sjogren's syndrome
CN112813099A (zh) *	2019-11-15	2021-05-18	上海细胞治疗集团有限公司	一种在活化的t细胞中具有高活性的启动子
AU2021320130B2 (en) *	2020-08-04	2025-11-20	Novartis Ag	Treatment of CLL
IL300086A (en)	2020-08-04	2023-03-01	Novartis Ag	Treatment of B-cell malignancies
CN118459585A (zh) *	2020-09-07	2024-08-09	白先宏	Baff-r结合分子及其应用
AU2021374083A1 (en) *	2020-11-06	2023-06-01	Novartis Ag	Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies
CN115073598B (zh) *	2021-03-15	2024-02-20	盛禾(中国)生物制药有限公司	一种抗baffr抗体及其应用
JP2024516019A (ja)	2021-05-04	2024-04-11	ノバルティスアーゲー	抗ｂａｆｆｒ抗体を使用する全身性エリテマトーデスのための治療
CN117203240A (zh)	2021-05-04	2023-12-08	诺华股份有限公司	使用抗baffr抗体治疗狼疮肾炎
AR127163A1 (es) *	2021-09-29	2023-12-27	Dragonfly Therapeutics Inc	Anticuerpos dirigidos a baff-r y uso de estos
EP4683948A1 (en)	2023-03-21	2026-01-28	Biograph 55, Inc.	Cd19/cd38 multispecific antibodies
WO2025058962A1 (en) *	2023-09-11	2025-03-20	Absci Corporation	High-throughput methods for kinetic characterization, quantifying and optimizing antibodies and antibody fragments expression in bacteria
WO2025131888A1 (en)	2023-12-19	2025-06-26	Basf Se	Modified alkoxylated polyalkylene imines or modified alkoxylated polyamines
WO2025221674A1 (en) *	2024-04-15	2025-10-23	Eli Lilly And Company	Baffr x cd3 bispecific antibodies and methods of use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1806143B1 (en) *	1999-08-17	2016-06-15	Biogen MA Inc.	Baff receptor (BCMA), an immunoregulatory agent
UA83458C2 (uk)	2000-09-18	2008-07-25	Байоджен Айдек Ма Інк.	Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
JP2008526205A (ja) *	2004-12-31	2008-07-24	ジェネンテック・インコーポレーテッド	Ｂｒ３に結合するポリペプチド及びその使用
WO2008008482A2 (en) *	2006-07-13	2008-01-17	Genentech, Inc.	Altered br3-binding polypeptides

2009
- 2009-07-15 WO PCT/EP2009/059030 patent/WO2010007082A1/en not_active Ceased
- 2009-07-15 DK DK09797499.2T patent/DK2315780T3/en active
- 2009-07-15 HR HRP20151227TT patent/HRP20151227T1/hr unknown
- 2009-07-15 RS RS20150667A patent/RS54299B1/sr unknown
- 2009-07-15 KR KR1020117001052A patent/KR101314369B1/ko active Active
- 2009-07-15 EA EA201100191A patent/EA024492B1/ru not_active IP Right Cessation
- 2009-07-15 PT PT97974992T patent/PT2315780E/pt unknown
- 2009-07-15 CA CA2730063A patent/CA2730063C/en active Active
- 2009-07-15 SI SI200931293T patent/SI2315780T1/sl unknown
- 2009-07-15 PE PE2011000038A patent/PE20110563A1/es active IP Right Grant
- 2009-07-15 ES ES09797499.2T patent/ES2547270T3/es active Active
- 2009-07-15 NZ NZ590057A patent/NZ590057A/xx unknown
- 2009-07-15 CN CN200980127408.2A patent/CN102119174B/zh active Active
- 2009-07-15 BR BRPI0915928A patent/BRPI0915928B8/pt active IP Right Grant
- 2009-07-15 UY UY0001031987A patent/UY31987A/es active IP Right Grant
- 2009-07-15 KR KR1020137019574A patent/KR101545795B1/ko active Active
- 2009-07-15 GE GEAP200912063A patent/GEP20146129B/en unknown
- 2009-07-15 AR ARP090102678A patent/AR072749A1/es active IP Right Grant
- 2009-07-15 US US12/503,175 patent/US8106163B2/en active Active
- 2009-07-15 MY MYPI2010005960A patent/MY158980A/en unknown
- 2009-07-15 HU HUE09797499A patent/HUE025778T2/en unknown
- 2009-07-15 PL PL09797499T patent/PL2315780T3/pl unknown
- 2009-07-15 AU AU2009272771A patent/AU2009272771B2/en active Active
- 2009-07-15 JP JP2011517915A patent/JP5767109B2/ja active Active
- 2009-07-15 EP EP09797499.2A patent/EP2315780B8/en active Active
- 2009-07-15 SG SG2013062567A patent/SG193805A1/en unknown
- 2009-07-15 MX MX2011000616A patent/MX2011000616A/es active IP Right Grant
- 2009-07-16 TW TW098124126A patent/TWI508742B/zh active
- 2009-07-16 JO JOP/2009/0267A patent/JO3149B1/ar active
2010
- 2010-12-13 ZA ZA2010/08952A patent/ZA201008952B/en unknown
- 2010-12-21 CR CR11863A patent/CR11863A/es unknown
2011
- 2011-01-06 IL IL210485A patent/IL210485A/en active IP Right Grant
- 2011-01-14 DO DO2011000016A patent/DOP2011000016A/es unknown
- 2011-01-14 MA MA33525A patent/MA32481B1/fr unknown
- 2011-01-14 NI NI201100017A patent/NI201100017A/es unknown
- 2011-01-14 CL CL2011000086A patent/CL2011000086A1/es unknown
- 2011-01-17 EC EC2011010761A patent/ECSP11010761A/es unknown
- 2011-01-17 CU CUP2011000013A patent/CU23878B1/es active IP Right Grant
- 2011-01-17 SV SV2011003807A patent/SV2011003807A/es unknown
- 2011-02-17 SM SM201100010T patent/SMP201100010B/it unknown
- 2011-12-15 US US13/326,569 patent/US9382326B2/en active Active
- 2011-12-15 US US13/326,514 patent/US9340620B2/en active Active
2015
- 2015-04-10 JP JP2015081099A patent/JP6077587B2/ja active Active
- 2015-10-19 CY CY20151100934T patent/CY1116800T1/el unknown

Also Published As

Publication number	Publication date
JO3149B1 (ar)	2017-09-20
BRPI0915928A2 (pt)	2015-11-03
BRPI0915928B8 (pt)	2021-05-25
IL210485A0 (en)	2011-03-31
HUE025778T2 (en)	2016-05-30
AR072749A1 (es)	2010-09-15
BRPI0915928B1 (pt)	2020-10-20
US9382326B2 (en)	2016-07-05
HRP20151227T1 (hr)	2015-12-18
SI2315780T1 (sl)	2015-11-30
CU20110013A7 (es)	2012-06-21
SMAP201100010A (it)	2011-05-06
US20120183529A1 (en)	2012-07-19
HK1150839A1 (en)	2012-01-13
DOP2011000016A (es)	2011-02-15
CL2011000086A1 (es)	2011-07-01
JP6077587B2 (ja)	2017-02-08
US20120195913A1 (en)	2012-08-02
CN102119174A (zh)	2011-07-06
RS54299B1 (sr)	2016-02-29
US9340620B2 (en)	2016-05-17
WO2010007082A1 (en)	2010-01-21
JP2015133983A (ja)	2015-07-27
EP2315780A1 (en)	2011-05-04
US8106163B2 (en)	2012-01-31
KR20130098432A (ko)	2013-09-04
NI201100017A (es)	2012-08-17
GEP20146129B (en)	2014-08-11
JP2011527896A (ja)	2011-11-10
EA024492B1 (ru)	2016-09-30
DK2315780T3 (en)	2015-10-19
ZA201008952B (en)	2012-01-25
MX2011000616A (es)	2011-02-24
TW201006493A (en)	2010-02-16
UY31987A (es)	2010-02-26
KR101314369B1 (ko)	2013-10-10
EA201100191A1 (ru)	2011-08-30
PE20110563A1 (es)	2011-08-29
JP5767109B2 (ja)	2015-08-19
SMP201100010B (it)	2011-09-09
MA32481B1 (fr)	2011-07-03
ECSP11010761A (es)	2011-02-28
CR11863A (es)	2011-02-11
IL210485A (en)	2015-03-31
SG193805A1 (en)	2013-10-30
CU23878B1 (es)	2013-04-19
AU2009272771B2 (en)	2012-09-20
KR101545795B1 (ko)	2015-08-19
CA2730063A1 (en)	2010-01-21
KR20110020914A (ko)	2011-03-03
EP2315780B8 (en)	2015-09-23
PT2315780E (pt)	2015-11-30
TWI508742B (zh)	2015-11-21
EP2315780B1 (en)	2015-08-19
CY1116800T1 (el)	2017-03-15
US20100021452A1 (en)	2010-01-28
ES2547270T3 (es)	2015-10-05
MY158980A (en)	2016-11-30
SV2011003807A (es)	2011-03-23
NZ590057A (en)	2012-08-31
AU2009272771A1 (en)	2010-01-21
CN102119174B (zh)	2015-01-21
CA2730063C (en)	2017-04-18

Publication	Publication Date	Title
ZA201008952B (en)	2012-01-25	Compositions and methods of use for therapeutic antibodies
IL248723B (en)	2018-03-29	Specific antibodies against the bcr complex and methods of using them
EP2448581A4 (en)	2013-02-20	THERAPEUTIC COMPOSITIONS AND METHODS OF USE THEREOF
SI2373691T1 (sl)	2019-05-31	Protitelesa proti FXI in postopki uporabe
ZA201005351B (en)	2012-09-26	Anti-cd79b antibodies and immunoconjugates and methods of use
IL213547A0 (en)	2011-07-31	Compounds and methods of use
IL219974A0 (en)	2012-07-31	Therapeutic compounds and related methods of use
ZA201101651B (en)	2012-06-27	Anti-notch2 antibodies and methods of use
PL2320911T3 (pl)	2015-01-30	Leki obkurczające naczynia krwionośne i sposoby ich wykorzystania
ZA201107555B (en)	2012-12-27	Anti-17f antibodies and methods of use thereof
EP2231665A4 (en)	2012-04-25	NEW COMPOSITIONS AND METHODS OF USE
PT2185719E (pt)	2014-02-20	Anticorpos anti-rantes e processos para a sua utilização
EP2242501A4 (en)	2011-10-19	THERAPEUTIC INHIBITORS OF PAI-I FUNCTION AND METHODS OF USE
IL207827A0 (en)	2010-12-30	Apoaequorin-containing compositions and methods of using same
ZA201004894B (en)	2011-05-25	Nuctraceutical composition and methods of use
ZA201004893B (en)	2011-05-25	Nuctraceutical composition and methods of use
GB0808326D0 (en)	2008-06-18	Compositions and methods for the treatment of fybromyalgia
HK1167143A (en)	2012-11-23	Therapeutic compositions and related methods of use
GB0820804D0 (en)	2008-12-24	Perinropril composition and method of use thereof